BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861]
URL: https://www.wjgnet.com/1948-5182/full/v26/i16/1861.htm
Number Citing Articles
1
Sahil Khanna, Neal S. Parikh, Lisa B. VanWagner. Fatty liver and cerebrovascular disease: plausible association and possible mechanismsCurrent Opinion in Lipidology 2022; 33(1): 31 doi: 10.1097/MOL.0000000000000799
2
Anika Niambi Al-Shura. Metabolic Disorders and Shen in Integrative Cardiovascular Chinese Medicine2021; : 17 doi: 10.1016/B978-0-12-818922-1.00003-9
3
Luca Miele, Cecilia Napodano, Alfredo Cesario, Antonio De Magistris, Krizia Pocino, Umberto Basile, Gian L. Rapaccini, Antonio Gasbarrini, Antonio Grieco. COVID‐19, adaptative immune response and metabolic‐associated liver diseaseLiver International 2021; 41(11): 2560 doi: 10.1111/liv.15061
4
Yu Jung Heo, Sung‐E Choi, Nami Lee, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine‐choline‐deficient diet mouse modelJournal of Gastroenterology and Hepatology 2021; 36(9): 2592 doi: 10.1111/jgh.15465
5
Shanshan Liu, Jialu Wang, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Shuangyuan Wang, Hong Lin, Zhiyun Zhao, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Yiping Xu, Weiqing Wang, Guang Ning, Yufang Bi, Mian Li, Yu Xu. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysisMetabolism 2021; 120: 154779 doi: 10.1016/j.metabol.2021.154779
6
Joselyn N. Allen, Adwitia Dey, Jingwei Cai, Jingtao Zhang, Yuan Tian, Mary Kennett, Yanling Ma, T. Jake Liang, Andrew D. Patterson, Pamela A. Hankey-Giblin. Metabolic Profiling Reveals Aggravated Non-Alcoholic Steatohepatitis in High-Fat High-Cholesterol Diet-Fed Apolipoprotein E-Deficient Mice Lacking Ron Receptor SignalingMetabolites 2020; 10(8): 326 doi: 10.3390/metabo10080326
7
Gabriel Tayguara Silveira Guerreiro, Larisse Longo, Mariana Alves Fonseca, Valessa Emanoele Gabriel de Souza, Mário Reis Álvares-da-Silva. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?Hepatology International 2021; 15(2): 380 doi: 10.1007/s12072-021-10157-y
8
Fan Yang, Ping Huang, Liandong Shi, Feng Liu, Aimei Tang, Shaohui Xu. <p>Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice</p>Drug Design, Development and Therapy 2020; : 3865 doi: 10.2147/DDDT.S258857
9
Yiyuan Zheng, Dan Fang, Chaoyuan Huang, Lina Zhao, Liming Gan, Youlan Chen, Fengbin Liu. Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver DiseaseFrontiers in Pharmacology 2022; 12 doi: 10.3389/fphar.2021.816032
10
Jawaher Alharthi, Mohammed Eslam. Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An UpdateJournal of Clinical and Translational Hepatology 2022; 10(1): 134 doi: 10.14218/JCTH.2021.00248
11
Sherine Ahmed Elsherif, Ahmed Salah Alm. Role of macrophages in liver cirrhosis: fibrogenesis and resolutionAnatomy & Cell Biology 2022; 55(1): 14 doi: 10.5115/acb.21.046
12
Lili Yu, Wei Hong, Shen Lu, Yanrong Li, Yaya Guan, Xiaogang Weng, Zhiwei Feng. The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and TreatmentFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.780496
13
Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, Henning Grønbæk. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?Expert Review of Gastroenterology & Hepatology 2021; 15(1): 51 doi: 10.1080/17474124.2020.1817740